Non-alcoholic fatty liver disease (NAFLD) is the commonest form of liver disease in primary care, with rates up to 25%.1 This figure, however, encompasses the whole spectrum of NAFLD from simple steatosis, non-alcoholic steatohepatitis (NASH) through to advanced fibrosis/cirrhosis. Due to the strong associ-ation with liver-related morbidity and premature death,2,3 fibrosis has become the main focus in secondary care for risk stratification, targeted lifestyle and metabolic risk management and drug trial recruitment. Indeed, all recent liver guidelines (EASL-EASD-EASO,4 AASLD,5 BSG,6 NICE)7 are in agreement in recommending screening for advanced fibrosis (histological stage Kleiner F3-4) in patients diagnosed with NAFLD. The man-agement of patien...
Non-alcoholic fatty liver disease (NAFLD) is a growing health p roblem with a global prevalence of o...
Abstract Non-alcoholic fatty liver disease (NAFLD) has emerged as a common cause of liver-related mo...
Background & AimsNon-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal LFTs in pri...
Non-alcoholic fatty liver disease (NAFLD) is the commonest form of liver disease in primary care, wi...
Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org...
Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in unselected populations and h...
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of about 25%. Incidence is increas...
The prevalence of non alcoholic fatty liver disease (NAFLD) has increased to 25% in the general popu...
BACKGROUND: The optimal strategy to support primary care practitioners (PCPs) to assess fibrosis sev...
Non-alcoholic fatty liver disease (NAFLD) affects at least 25% of the general population and is an i...
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent and potentially severe liver ...
Nonalcoholic fatty liver disease (NAFLD) is becoming the most prevalent liver disease worldwide, ass...
Background & Aims: the development of non-invasive liver fibrosis tests may enable earlier ident...
International audienceDespite the high prevalence of non-alcoholic fatty liver disease (NAFLD) in pr...
Primary care physicians (PCPs) have the primary role in the diagnosis and management of nonalcoholic...
Non-alcoholic fatty liver disease (NAFLD) is a growing health p roblem with a global prevalence of o...
Abstract Non-alcoholic fatty liver disease (NAFLD) has emerged as a common cause of liver-related mo...
Background & AimsNon-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal LFTs in pri...
Non-alcoholic fatty liver disease (NAFLD) is the commonest form of liver disease in primary care, wi...
Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org...
Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in unselected populations and h...
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of about 25%. Incidence is increas...
The prevalence of non alcoholic fatty liver disease (NAFLD) has increased to 25% in the general popu...
BACKGROUND: The optimal strategy to support primary care practitioners (PCPs) to assess fibrosis sev...
Non-alcoholic fatty liver disease (NAFLD) affects at least 25% of the general population and is an i...
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent and potentially severe liver ...
Nonalcoholic fatty liver disease (NAFLD) is becoming the most prevalent liver disease worldwide, ass...
Background & Aims: the development of non-invasive liver fibrosis tests may enable earlier ident...
International audienceDespite the high prevalence of non-alcoholic fatty liver disease (NAFLD) in pr...
Primary care physicians (PCPs) have the primary role in the diagnosis and management of nonalcoholic...
Non-alcoholic fatty liver disease (NAFLD) is a growing health p roblem with a global prevalence of o...
Abstract Non-alcoholic fatty liver disease (NAFLD) has emerged as a common cause of liver-related mo...
Background & AimsNon-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal LFTs in pri...